Health state utility values by cancer stage: a systematic literature review

Mir-Masoud Pourrahmat, Ashley Kim (), Anuraag R. Kansal, Marg Hux, Divya Pushkarna, Mir Sohail Fazeli and Karen C. Chung
Additional contact information
Mir-Masoud Pourrahmat: Evidinno Outcomes Research Inc.
Ashley Kim: GRAIL, Inc.
Anuraag R. Kansal: GRAIL, Inc.
Marg Hux: Evidinno Outcomes Research Inc.
Divya Pushkarna: Evidinno Outcomes Research Inc.
Mir Sohail Fazeli: Evidinno Outcomes Research Inc.
Karen C. Chung: GRAIL, Inc.

The European Journal of Health Economics, 2021, vol. 22, issue 8, No 9, 1275-1288

Abstract: Abstract Objectives Cancer diagnoses at later stages are associated with a decrease in health-related quality of life (HRQOL). Health state utility values (HSUVs) reflect preference-based HRQOL and can vary based on cancer type, stage, treatment, and disease progression. Detecting and treating cancer at earlier stages may lead to improved HRQOL, which is important for value assessments. We describe published HSUVs by cancer type and stage. Methods A systematic review was conducted using Embase, MEDLINE®, EconLit, and gray literature to identify studies published from January 1999 to September 2019 that reported HSUVs by cancer type and stage. Disutility values were calculated from differences in reported HSUVs across cancer stages. Results From 13,872 publications, 27 were eligible for evidence synthesis. The most frequent cancer types were breast (n = 9), lung (n = 5), colorectal (n = 4), and cervical cancer (n = 3). Mean HSUVs decreased with increased cancer stage, with consistently lower values seen in stage IV or later-stage cancer across studies (e.g., − 0.74, − 0.44, and − 0.51 for breast, colorectal, and cervical cancer, respectively). Disutility values were highest between later-stage (metastatic or stage IV) cancers compared to earlier-stage (localized or stage I–III) cancers. Conclusions This study provides a summary of HSUVs across different cancer types and stages that can inform economic evaluations. Despite the large variation in HSUVs overall, a consistent decline in HSUVs can be seen in the later stages, including stage IV. These findings indicate substantial impairment on individuals’ quality of life and suggest value in early detection and intervention.

Keywords: Health state utility; Disutility; Cancer; Cancer stage; Breast cancer; Lung cancer; Colorectal cancer; Cervical cancer; Systematic literature review (search for similar items in EconPapers)
JEL-codes: I00 I10 (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-021-01335-8 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:22:y:2021:i:8:d:10.1007_s10198-021-01335-8

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-021-01335-8

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().